

Product datasheet for **TL303952V**

IL1RA (IL1RN) Human shRNA Lentiviral Particle (Locus ID 3557)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	IL1RA (IL1RN) Human shRNA Lentiviral Particle (Locus ID 3557)
Locus ID:	3557
Synonyms:	DIRA; ICIL-1RA; IL-1ra; IL-1ra3; IL-1RN; IL1F3; IL1RA; IRAP; MVCD4
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	IL1RN - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_000577 , NM_001318914 , NM_173841 , NM_173842 , NM_173843 , NM_173843.1 , NM_173843.2 , NM_000577.1 , NM_000577.2 , NM_000577.4 , NM_173841.1 , NM_173841.2 , NM_173842.1 , NM_173842.2 , BC009745 , BC009745.2 , BC068441 , NM_173841.3 , NM_173842.3
UniProt ID:	P18510
Summary:	The protein encoded by this gene is a member of the interleukin 1 cytokine family. This protein inhibits the activities of interleukin 1, alpha (IL1A) and interleukin 1, beta (IL1B), and modulates a variety of interleukin 1 related immune and inflammatory responses, particularly in the acute phase of infection and inflammation. This gene and five other closely related cytokine genes form a gene cluster spanning approximately 400 kb on chromosome 2. A polymorphism of this gene is reported to be associated with increased risk of osteoporotic fractures and gastric cancer. Several alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Aug 2020]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).